Skip to content
DataLookout
Menu

NCT04494113

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 128 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion date changed from estimate of Nov 30, 2026 to Aug 14, 2026
    • Study completion pushed from Nov 30, 2026 to Nov 12, 2027
  2. Notable Eligibility criteria shortened, about 20 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description revised
    • Site details revised at 1 of 7 sites
  3. Notable Primary and study completion pushed from Jun 1, 2026 to Nov 30, 2026v125
  4. Notable Trial status: Suspended to Active, Not Recruitingv87
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Pharmacodynamic response
Timeframe: Up to 6-8 hours post-triapine infusion

Secondary (2)

Incidence of adverse events
Pharmacokinetic (PK) analysis

Arms and interventions

Treatment (triapine, surgical resection)Experimental

Patients receive triapine IV over 2 hours on day 1. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion. Patients also undergo biopsy and collection of blood samples on study.

Procedures: Biopsy Procedure, Biospecimen Collection, Resection

Drugs: Triapine

Sites

7 sites in 1 country